Once-weekly semaglutide 7.2 mg in adults with obesity
study054
10.1016/S0140-6736(24)01448-5
The Lancet
randomized clinical trial
Higher-dose semaglutide 7.2 mg was evaluated in adults with obesity.
Higher-dose semaglutide improved weight outcomes versus placebo in the STEP UP program.
semaglutide
fat-loss|metabolism
metabolic-stack
semaglutide-vs-tirzepatide
published